Analysts Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Target Price at $8.83

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has received a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $8.83.

MRNS has been the topic of a number of research analyst reports. EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a report on Monday, September 23rd. StockNews.com upgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Marinus Pharmaceuticals in a research report on Wednesday, August 14th. Finally, Truist Financial reaffirmed a “buy” rating and set a $10.00 price objective on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th.

Marinus Pharmaceuticals Trading Up 2.9 %

MRNS opened at $1.78 on Monday. Marinus Pharmaceuticals has a 12-month low of $1.05 and a 12-month high of $11.26. The company has a debt-to-equity ratio of 5.68, a current ratio of 2.28 and a quick ratio of 2.15. The stock has a market capitalization of $97.78 million, a PE ratio of -0.67 and a beta of 1.14. The firm’s fifty day moving average price is $1.44 and its 200 day moving average price is $2.27.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The company had revenue of $8.06 million during the quarter, compared to analyst estimates of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same quarter last year, the company posted ($0.61) EPS. As a group, research analysts expect that Marinus Pharmaceuticals will post -1.88 EPS for the current fiscal year.

Institutional Trading of Marinus Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC increased its holdings in shares of Marinus Pharmaceuticals by 31.4% during the first quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock valued at $37,431,000 after purchasing an additional 990,607 shares during the period. Acadian Asset Management LLC acquired a new position in Marinus Pharmaceuticals during the 2nd quarter valued at about $813,000. Renaissance Technologies LLC acquired a new position in Marinus Pharmaceuticals during the 2nd quarter valued at about $727,000. Superstring Capital Management LP bought a new stake in shares of Marinus Pharmaceuticals during the 4th quarter worth about $5,027,000. Finally, XTX Topco Ltd acquired a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter worth approximately $232,000. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.